3.61  -0.2 (-5.25%)		10-16 16:00
Open: 3.76 High: 3.84 Volume: 317,868		Pre. Close: 3.81 Low: 3.61 Market Cap: 249(M)

Short term
Mid term
Targets	6-month :	4.41	1-year :	4.82
Resists	First :	3.78	Second :	4.13
Pivot price	3.84
Supports	First :	3.22	Second :	2.67
MAs	MA(5) :	3.77	MA(20) :	3.86
	MA(100) :	3.94	MA(250) :	3.25
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	17.3	D(3) :	27.7
RSI	RSI(14): 43.2
52-week	High :	4.57	Low :	2.07

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ OSUR ] has closed below the lower bollinger band by 0.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ OSUR ] is to continue within current trading range. Bollinger Bands are 34% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.84 - 3.86	3.86 - 3.88
Low:	3.56 - 3.58	3.58 - 3.6
Close:	3.57 - 3.6	3.6 - 3.64

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.

Sat, 17 Oct 2026
OraSure Technologies stock sits above its USD 3.00 consensus target - ad-hoc-news.de

Thu, 15 Oct 2026
OraSure Technologies (NASDAQ:OSUR) Stock Crosses Above 200-Day Moving Average - Here's Why - MarketBeat

Thu, 01 Oct 2026
A 4,797-share grant replaces cash fees for OraSure (OSUR) director Steven Kyle Boyd. - Stock Titan

Tue, 29 Sep 2026
OraSure Technologies (NASDAQ:OSUR) Stock Price Crosses Above 200 Day Moving Average - Here's Why - MarketBeat

Mon, 21 Sep 2026
Weekly Recap: Investor group for OraSure (OSUR) and Yorkville-Islet filings - TradingView

Sun, 06 Sep 2026
OraSure (OSUR) Returns To Profit, But Growth Remains Elusive - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	69 (M)
Shares Float	57 (M)
Held by Insiders	6.4 (%)
Held by Institutions	89 (%)
Shares Short	2,930 (K)
Shares Short P.Month	3,130 (K)

EPS	-0.69
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.61
Profit Margin	-43.8 %
Operating Margin	-56 %
Return on Assets (ttm)	-11.1 %
Return on Equity (ttm)	-14.1 %
Qtrly Rev. Growth	-1.9 %
Gross Profit (p.s.)	0.69
Sales Per Share	1.62
EBITDA (p.s.)	-0.9
Qtrly Earnings Growth	0 %
Operating Cash Flow	-43 (M)
Levered Free Cash Flow	-45 (M)

PE Ratio	-5.24
PEG Ratio	6.1
Price to Book value	0.78
Price to Sales	2.21
Price to Cash Flow	-5.81

Dividend	1.6
Forward Dividend	0
Dividend Yield	44.3%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.